Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging

Clinical Radiology

Volumn 55, Issue 9, 2000, Pages 690-695

  Saini, S ^a,b   Sharma, R ^a,b   Baron, R L ^a,c   Turner, D A ^a,d   Ros, P R ^a,b   Hahn, P F ^a,b   Small, W C ^a,e   Delange, E E ^a,f   Stillman, A E ^a,g   Edelman, R R ^a,b   Runge, V M ^a,h   Outwater, E K ^a,i  

^a Departments of Radiology   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Contrast media; Liver; MR imaging

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; IRON; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMANGIOMA; HUMAN; IMAGE ANALYSIS; LIVER INJURY; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METASTASIS; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL DETECTION; STATISTICAL ANALYSIS;

EID: 0034522949     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1053/crad.2000.0504     Document Type: Article

References (13)

1. Contrast-enhanced MR imaging of the liver
2. Liver MR imaging with iron oxides: Toward consensus and clinical practice
3. Hepatic MR imaging with Ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
4. Surface properties of superparamagnetic iron oxide contrast agents: Ferumoxides, ferumoxtran, ferumoxsil
5. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil
6. Phase I clinical evaluation of a new iron oxide MR contrast agent
7. Liver-specific MR imaging contrast agents
8. Safety profile of USPIO ferumoxtran-10: Phase-II clinical trail data
9. Detection of HCC arising in cirrhotic livers: Comparison of gadolinium- and ferumoxides-enhanced MR imaging
10. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227)
11. Differentiation of liver hemangiomas from metastasis and hepatocellular carcinoma at MR imaging with blood-pool contrast agent Code 7227
12. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
13. MR contrast material for vascular enhancement: Value of superparamagnetic iron oxide